Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis

Company Overview

Whitehawk Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s work centers on precision medicines intended to selectively target diseased cells while limiting damage to healthy tissue.

Whitehawk Therapeutics is advancing a pipeline of investigational therapeutic programs, with development activities focused primarily on oncology. As a clinical-stage company, its product candidates remain subject to preclinical and clinical testing, as well as review by applicable regulatory authorities, before any potential commercialization.

Publicly available information about the company’s specific pipeline, geographic operations, and leadership is limited. Whitehawk Therapeutics is headquartered in the United States and is listed on the Nasdaq under the symbol WHWK.

Key Stats

• Today's Range: $3.55 to $3.72
• 50-Day Range: $3.61 to $5.08
• 52-Week Range: $1.87 to $5.49
• Volume: 468,147 shs
• Average Volume: 369,005 shs
• Market Capitalization: $205.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.33
• Consensus Rating: Moderate Buy

Whitehawk Therapeutics Stock Analysis - MarketRank™

Whitehawk Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 429th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Whitehawk Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Whitehawk Therapeutics has a consensus price target of $8.33, representing about 130.8% upside from its current price of $3.61.

Amount of Analyst Coverage

Whitehawk Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Whitehawk Therapeutics are expected to grow in the coming year, from ($1.07) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Whitehawk Therapeutics is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Whitehawk Therapeutics is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Whitehawk Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.55% of the float of Whitehawk Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Whitehawk Therapeutics has a short interest ratio ("days to cover") of 9.32.

Change versus previous month

Short interest in Whitehawk Therapeutics has recently decreased by 8.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Whitehawk Therapeutics does not currently pay a dividend.

Dividend Growth

Whitehawk Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.24

News Sentiment

Whitehawk Therapeutics has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Whitehawk Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Whitehawk Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

49.90% of the stock of Whitehawk Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.08% of the stock of Whitehawk Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:WHWK
• CIK: 1422142
• Web: www.whitehawktx.com
• Phone: (551) 321-2234
• Fax: N/A
• Employees: 23
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Whitehawk Therapeutics: $8.33
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +130.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.89%
• Return on Assets: -49.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.38
• Quick Ratio: 17.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.89 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 57,009,000
• Free Float: 28,562,000
• Market Cap: $205.80 million
• Optionable: N/A
• Beta: 0.92